PMS47 - COST-EFFECTIVENESS OF TOFACITINIB COMPARED WITH ADALIMUMAB IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN IRAN
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.1761
https://www.valueinhealthjournal.com/article/S1098-3015(18)35063-0/fulltext
Title :
PMS47 - COST-EFFECTIVENESS OF TOFACITINIB COMPARED WITH ADALIMUMAB IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN IRAN
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35063-0&doi=10.1016/j.jval.2018.09.1761
First page :
Section Title :
Open access? :
No
Section Order :
1123